Waters Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Waters in the last year. There are currently 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Waters stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in WAT, but not buy additional shares or sell existing shares.
View analyst ratings for Waters or view top-rated stocks.

7 Wall Street research analysts have issued 1-year price targets for Waters' stock. Their WAT stock forecasts range from $315.00 to $400.00. On average, they predict Waters' stock price to reach $361.00 in the next twelve months. This suggests a possible upside of 8.9% from the stock's current price.
View analysts' price targets for Waters or view top-rated stocks among Wall Street analysts.

Waters' stock was trading at $372.60 at the beginning of 2022. Since then, WAT shares have decreased by 11.1% and is now trading at $331.39.
View the best growth stocks for 2022 here.

Waters is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Waters.

Waters Co. (NYSE:WAT) announced its earnings results on Tuesday, May, 3rd. The medical instruments supplier reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.32 by $0.48. The medical instruments supplier earned $690.60 million during the quarter, compared to analysts' expectations of $634.08 million. Waters had a trailing twelve-month return on equity of 221.08% and a net margin of 24.57%. The firm's quarterly revenue was up 13.5% on a year-over-year basis. During the same quarter last year, the firm earned $2.29 earnings per share.
View Waters' earnings history.

Waters issued an update on its second quarter 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of $2.55-$2.65 for the period, compared to the consensus EPS estimate of $2.78. The company issued revenue guidance of $695.28 million-$708.91 million, compared to the consensus revenue estimate of $706.48 million.

13 employees have rated Waters CEO Udit Batra on Glassdoor.com. Udit Batra has an approval rating of 100% among Waters' employees. This puts Udit Batra in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Waters include Thermo Fisher Scientific (TMO), Agilent Technologies (A), Illumina (ILMN), Mettler-Toledo International (MTD), PerkinElmer (PKI), Bio-Rad Laboratories (BIO), Bio-Techne (TECH), Charles River Laboratories International (CRL), Bruker (BRKR), Pacific Biosciences of California (PACB), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD).
View all of WAT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Waters investors own include Thermo Fisher Scientific (TMO), (HON), Raytheon Technologies (RTX), CVS Health (CVS), Home Depot (HD), Johnson & Johnson (JNJ), Abbott Laboratories (ABT), Verizon Communications (VZ), Cisco Systems (CSCO) and Walmart (WMT).

Waters trades on the New York Stock Exchange (NYSE) under the ticker symbol "WAT."

Waters' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (11.10%), BlackRock Inc. (10.14%), Bank of New York Mellon Corp (6.61%), State Street Corp (4.54%), Massachusetts Financial Services Co. MA (4.09%) and Wellington Management Group LLP (2.50%). Company insiders that own Waters stock include Christopher A Kuebler, Christopher J Oconnell, Edward Conard, Elizabeth B Rae, Francis Kim, Ian King, Joann A Reed, Keeley A Aleman, Laurie H MD Glimcher, Linda Baddour, Mark T Beaudouin, Michael C Harrington, Michael J Berendt, Robert G Carson, Sherry Buck and Thomas P Salice.
View institutional ownership trends for Waters.

WAT stock was sold by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, Invesco Ltd., Marathon Asset Management Ltd, Los Angeles Capital Management LLC, Massachusetts Financial Services Co. MA, Bank of New York Mellon Corp, Acadian Asset Management LLC, and First Trust Advisors LP. Company insiders that have sold Waters company stock in the last two years include Christopher A Kuebler, Christopher J Oconnell, Edward Conard, Ian King, Joann A Reed, Linda Baddour, Michael C Harrington, Michael J Berendt, Robert G Carson, Sherry Buck, and Thomas P Salice.
View insider buying and selling activity for Waters or view top insider-selling stocks.

WAT stock was purchased by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Renaissance Technologies LLC, Boston Trust Walden Corp, Tikehau Investment Management, Nordea Investment Management AB, KBC Group NV, Caisse DE Depot ET Placement DU Quebec, and BlackRock Inc..
View insider buying and selling activity for Waters or or view top insider-buying stocks.

Shares of WAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of WAT stock can currently be purchased for approximately $331.39.

Waters (NYSE:WAT) has a market capitalization of $19.96 billion and generates $2.79 billion in revenue each year. The medical instruments supplier earns $692.84 million in net income (profit) each year or $11.43 on an earnings per share basis.

Waters employs 7,800 workers across the globe.

Waters was founded in 1958.

Waters' mailing address is 34 MAPLE STREET, MILFORD MA, 01757. The official website for Waters is www.waters.com. The medical instruments supplier can be reached via phone at (508) 478-2000, via email at [email protected], or via fax at 508-872-1990.